Strides Bengaluru unit gets 'Voluntary Indicated Action' status from USFDA

The flagship facility in Bengaluru is the largest manufacturing facility for the company with capabilities to produce finished dosage products across multiple formats

drugs, generics, drug, pharma, pharmaceuticals, medicines, tablets, capsules, healthcare, IPR
Some major Western concerns about India's patent framework are the definitions of inventions and provisions for compulsory licensing
Gireesh Babu Chennai
1 min read Last Updated : Jul 20 2019 | 10:17 AM IST
Strides Pharma Science Limited today announced that its formulation facility in Bengaluru went through a United States food and drug adiministration (USFDA) inspection that ended on May 24th, 2019.  

The inspection was completed successfully with a Voluntary Action Indicated (VAI)  classification, said the company.

As per USFDA, VAI means that though "objectionable practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action”.

The flagship facility in Bengaluru is the largest manufacturing  facility for the company with capabilities to produce finished dosage products across multiple formats including capsules, ointments, creams and liquids. 

The Banglore facility services the key regulated markets of the US, Europe, and Australia.

As per the USFDA, VAI means that though “objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action”.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :USFDAStrides Pharma

Next Story